From a dedicated share holder: These four PR's

From a dedicated share holder:

These four PR's tell the clear story of ALRT:

September 19, 2017 ALRT receives FDA clearance for insulin dose adjustment:
https://www.globenewswire.com/news-release/20...nsion.html

May 14, 2018 ALRT is developed for enterprise scare:
https://www.globenewswire.com/news-release/20...Scale.html

June 28, 2018 ALRT secures reimbursement by bundling with glucose monitor/test supplies:
https://www.globenewswire.com/news-release/20...ution.html

On August 27th and October 1st of 2018 two marketing PR's were released

April 02, 2019 6 months later ALRT is revamped with cutting edge features:
https://www.globenewswire.com/news-release/20...betes.html

The above PR timeline show's a step by step history to get us to where we are today, ready to go live with what sounds like a lot of clients in the pipeline. There was obviously a pivot from MENA/India to US/Canada/Asia while ALRT was updated (features listed in the April PR) over those six months.

Besides offering this timeline for new comers, I wanted to point out that those of us who have been here for years made that decision based off long term value. If you're not in it for the long term it's "silly" to have invested before revenue generating PR's are announced.

Here some info on ALRT competitor Livongo (to consolidate stickies):

For all of you who do not follow the IPO market, Livongo will be going public. This video explains how Livongo works and is a great video to help understand how diabetes management platforms work in general if you are unfamiliar: https://m.youtube.com/watch?v=tJ_ggQnNWQI. In comparison, here is a video of ALRT: https://www.youtube.com/watch?v=b8TgPOGYCKs.

The IPO was originally priced at 10x forward earnings of an expected $150 million (Per the S-1 SEC filing annual revenue was just $68 million) and that has just been raised taking the expected market cap from $1.5B to $2.3B as of 7-22-19 resulting in a 15+ forward earnings market cap. Here is a great article to for more understanding: https://seekingalpha.com/article/4276056-livo...-10x-sales

Now, the reason I bring all this up is for a couple of reasons.
#1, Livongo is a close competitor to ALRT but it is a significantly inferior product and cannot offer predictive A1C or insulin dose adjustment which are both critical.
#2, Besides those features, ALRT is unlike any other management platform in that they address the number one issue in diabetes management which is non-adherent patient care. ALRT works with the patient and CAREGIVER and alerts of any issues so that they can contact the patient.
#3, I believe Livongo gives the most accurate representation to compare the future of ALRT to in terms of growth, revenue, and price evaluation.

I know a few shareholders are restless and anxious for news, but I really cannot overstate the importance of patience (IMO). When ALRT goes live with actual users we will get the snowball effect and growth will be very fast in my opinion. I believe Mr. Chan has a number of deals/agreements in the works both domestically and internationally and when they come to fruition over the coming days/weeks/months we will see PR's, but more importantly we will see the beginning of growth in the share price. Hopefully everybody who has been here over the past few years recognizes the potential and does not short change themselves if the PPS doubles or triples... I have always believed this is a multi-dollar (not penny) stock in the making for those with the foresight and patience to see it through. Hopefully Livongo proves to be a good example of that to other shareholders.